Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 9/20 | 0.35 |
| ▸ | FEN1 | P39748 | 9/20 | 0.35 |
| ▸ | TYK2 | P29597 | 5/20 | 0.34 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20150274 | 0.85 | TYK2 (0.33) | ALOX5APFEN1TYK2AOC3CHRM2 | |
| SCHEMBL24775869 | 0.77 | AOC3 (0.33) | ALOX5APFEN1TYK2AOC3CHRM2 | |
| SCHEMBL30079490 | 0.77 | TYK2 (0.41) | TYK2AOC3CHRM2CHRM3 | |
| SCHEMBL15698663 | 0.77 | TYK2 (0.41) | TYK2AOC3CHRM2CHRM3 | |
| SCHEMBL30079457 | 0.75 | TYK2 (0.35) | ALOX5APFEN1TYK2AOC3CHRM2 | |
| SCHEMBL24776721 | 0.75 | TYK2 (0.35) | ALOX5APFEN1TYK2AOC3CHRM2 | |
| SCHEMBL24822834 | 0.75 | TYK2 (0.35) | ALOX5APFEN1TYK2AOC3CHRM2 | |
| SCHEMBL29947295 | 0.75 | TYK2 (0.35) | ALOX5APFEN1TYK2AOC3CHRM2 | |
| SCHEMBL24776105 | 0.74 | FYN (0.33) | ALOX5APFEN1TYK2AOC3CHRM2 | |
| SCHEMBL29947259 | 0.74 | FYN (0.33) | ALOX5APFEN1TYK2AOC3CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163004-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2025-05-22 | — | — | US | disclosed |
| US-20240190829-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2024-06-13 | — | — | US | disclosed |
| CN-117794912-A | Substituted heterocyclic compounds | 百时美施贵宝公司 | 2024-03-29 | — | — | CN | disclosed |
| EP-4337655-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | Bristol-Myers Squibb Company (US) | 2024-03-20 | — | — | EP | disclosed |
| US-11866414-B2 | Substituted heterocyclic compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-01-09 | — | — | US | disclosed |
| US-20220411384-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2022-12-29 | — | — | US | disclosed |
| US-20220411384-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2022-12-29 | — | — | US | disclosed |
| WO-2022241171-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11866414-B2 | Substituted heterocyclic compounds | TYK2, JAK2, STAT3 | ALOX5AP 3808/4885FEN1 4033/4885TYK2 1/4885 |
| US-20250163004-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | TYK2, JAK2, STAT3 | ALOX5AP 3808/4885FEN1 4033/4885TYK2 1/4885 |
| US-20220411384-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | TYK2, JAK2, STAT3 | ALOX5AP 3808/4885FEN1 4033/4885TYK2 1/4885 |
| US-20240190829-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | TYK2, JAK2, STAT3 | ALOX5AP 3808/4885FEN1 4033/4885TYK2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.